Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CL2020
Previous Study | Return to List | Next Study

The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy (SHIELD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04261335
Recruitment Status : Recruiting
First Posted : February 7, 2020
Last Update Posted : March 5, 2020
Sponsor:
Collaborator:
Life Science Institute, Inc.
Information provided by (Responsible Party):
Yoshiaki Sato, Nagoya University

Brief Summary:
The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will evaluate the efficacy of CL2020 cells for infant development.

Condition or disease Intervention/treatment Phase
Hypoxia-Ischemia, Brain Biological: CL2020 cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: 3 + 3 dose escalation study design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial
Actual Study Start Date : March 4, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Chlorine

Arm Intervention/treatment
Experimental: CL2020 cells
Intravenous injection of CL2020 cells
Biological: CL2020 cells
1.5 million or 15 million cells, IV on day 5 to 14 of birth




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: until 12 weeks after the administration ]
    Any adverse events are summarized.


Secondary Outcome Measures :
  1. Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators) [ Time Frame: at 12, 26, 38, 52, and 78 weeks after administration ]
    Incidence of composite endpoints is summarized.

  2. Mortality [ Time Frame: all of the clinical trial period (up to 44 months) ]
    Mortality is summarized.

  3. Overall survival [ Time Frame: all of the clinical trial period (up to 44 months) ]
    Overall survival is summarized.

  4. Duration of continuous respiratory support [ Time Frame: up to 78 weeks ]
    Duration of continuous respiratory support is summarized.

  5. Duration of continuous use of vasopressors or pulmonary vasodilators [ Time Frame: up to 78 weeks ]
    Duration of continuous use of vasopressors or pulmonary vasodilators is summarized.

  6. The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition [ Time Frame: 78 weeks after administration ]
    Each composite scores are summarized. The higher scores mean a better outcome.

  7. The developmental quotient in Kyoto Scale of Psychological Development 2001 [ Time Frame: 78 weeks after administration ]
    The developmental quotient is summarized. The higher scores mean a better outcome.

  8. Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words [ Time Frame: at 26, 38, 52, and 78weeks after administration ]
    Presence of each event is summarized.

  9. Presence of spasticity [ Time Frame: at 12, 26, 38, 52, and 78 weeks after administration ]
    Presence of spasticity is summarized. Spasticity is the condition as below: increased muscle tone, or increased deep tendon reflex.

  10. Presence of epilepsy [ Time Frame: until 78 weeks after administration ]
    Presence of spasticity is summarized. The definition of epilepsy is the condition based on the International League Against Epilepsy.

  11. MRI score [ Time Frame: at 2, and 78 weeks after administration ]
    MRI score is summarized. The scoring system is based on the report of Barkovich AJ, et al. (AJNR Am J Neuroradiol. 1998 ;19(1):143-9.) . The higher scores mean a worse outcome.

  12. Gross Motor Function Classification System (GMFCS) score [ Time Frame: at 78 weeks after administration ]
    GMFCS score is summarized. The gross motor function can be categorized into 5 different level. The higher scores mean a worse outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 14 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At least 36 weeks gestation, and either one of the following criteria (i.-iii.) i. Apgar score ≤5 at 10 minutes ii. Continued resuscitation for at least 10 minutes iii. pH <7.0 or base deficit ≥16 mmol/L in any blood sample obtained within 60 min of birth
  2. Moderate or severe encephalopathy by a Sarnat criteria
  3. Undergone therapeutic hypothermia started before six hours of birth, and done for 72 hours continuously
  4. Birth weight ≥1,800 g
  5. Heart rate ≥100/min, and SpO2 ≥90 %
  6. Able to provide voluntary written consent after receiving adequate information about the study (consent will be obtained from an acceptable representative)

Exclusion Criteria:

  1. Suspected or confirmed severe congenital abnormalities or chromosomal anomaly
  2. Planned to undergo surgery or radiation therapy
  3. Scheduled to take systemic corticosteroids treatment for over five days
  4. Blood glucose ≥ 200 mg/dL
  5. Participation in another clinical study (not exclude patients in observational studies)
  6. Suspected or confirmed active and severe infection
  7. Positive for HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody or syphilis serum reaction
  8. History of severe hypersensitivity or anaphylactic reaction
  9. Severe complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04261335


Contacts
Layout table for location contacts
Contact: Yoshiaki Sato, MD, PhD +81-52-741-2985 yoshiaki@med.nagoya-u.ac.jp
Contact: Kazuto Ueda, MD +81-52-744-2985 ueda.kazuto@med.nagoya-u.ac.jp

Locations
Layout table for location information
Japan
Nagoya University Hospital Recruiting
Nagoya, Aich, Japan, 466-8560
Contact: Yoshiaki Sato, MD, Ph.D    +81-52-741-2985    yoshiaki@med.nagoya-u.ac.jp   
Sponsors and Collaborators
Nagoya University
Life Science Institute, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Yoshiaki Sato, MD, PhD Department of Center for Maternal Neonatal Care, Nagoya University Hospital
Layout table for additonal information
Responsible Party: Yoshiaki Sato, MD, PhD, Associate Professor at Department of Center for Maternal Neonatal Care, Nagoya University Hospital, Nagoya University
ClinicalTrials.gov Identifier: NCT04261335    
Other Study ID Numbers: CAMCR-014
jRCT2043190112 ( Registry Identifier: Japan Registry of Clinical Trials )
First Posted: February 7, 2020    Key Record Dates
Last Update Posted: March 5, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yoshiaki Sato, Nagoya University:
Hypoxia-Ischemia, Brain
Infant, Newborn
Mesenchymal Stem Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Brain Ischemia
Hypoxia-Ischemia, Brain
Ischemia
Hypoxia
Pathologic Processes
Signs and Symptoms, Respiratory
Central Nervous System Diseases
Nervous System Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Hypoxia, Brain